Updated
Anixa BiosciencesANIX · Healthcare
$3.18+4.95%
Market cap$110M
IndustryBiotechnology
Anixa Biosciences (ANIX) Financial statements
Net income was -$11M.
Key figures
The diluted share count rose 271% over the period (dilution).
- Revenue, FY2025
- —
- Net income
- -$11M-13.0% on 2024
- Operating margin
- —
- Free cash flow
- —
Revenue and free cash flow
Fiscal years, from Anixa Biosciences's 10-K filings.
Anixa Biosciences revenue and free cash flow
FY2016–FY2025ANIXRevenue$0MANIXFree cash flow-$6M
Margins
How much of each dollar of revenue is left after the cost of sales, after operating costs, and at the bottom line.
Anixa Biosciences margins
FY2016–FY2025ANIXOperating margin-6586%ANIXNet margin-5978%
Financial statements
Fiscal 2016–2025.
Anixa Biosciences income statement, fiscal 2016–2025
| USD | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $300,000 | $362,500 | $1M | $250,000 | — | $512,000 | — | $210,000 | $210,000 | — |
| Research and development | $2M | $2M | $7M | $5M | $4M | $6M | $7M | $5M | $6M | $5M |
| Selling, general and admin | $3M | $4M | $7M | $6M | $6M | $7M | $7M | $6M | $7M | $7M |
| Operating income | -$5M | -$6M | -$14M | -$12M | -$10M | -$13M | -$14M | -$11M | -$14M | -$12M |
| Interest expense | $519,946 | $500,455 | — | — | — | — | — | — | — | — |
| Pre-tax income | -$5M | -$5M | -$14M | -$12M | — | — | — | — | — | — |
| Net income | -$5M | -$5M | -$14M | -$12M | -$10M | -$13M | -$14M | -$10M | -$13M | -$11M |
| EPS (diluted) | -$0.57 | -$0.58 | -$0.79 | -$0.59 | -$0.45 | -$0.45 | $0.45 | -$0.32 | -$0.39 | -$0.34 |
| Diluted shares | 9M | 12M | 18M | 20M | 22M | 29M | 0M | 31M | 32M | 32M |
| Operating margin | -1503.0% | -1676.0% | -1284.4% | -4756.0% | — | -2565.6% | — | -5243.3% | -6586.2% | — |
| Net margin | -1672.1% | -1381.8% | -1258.1% | -4658.8% | — | -2530.1% | — | -4671.9% | -5978.1% | — |
Anixa Biosciences balance sheet, fiscal 2016–2025
| USD | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $3M | $7M | $5M | $6M | $9M | $36M | $30M | $24M | $20M | $15M |
| Receivables | — | — | $306,991 | $66,527 | $2,231 | — | $46,000 | $270,000 | $173,000 | — |
| Total current assets | $3M | $7M | $6M | $6M | $9M | $36M | $30M | $25M | $21M | $16M |
| Property, plant and equipment | $156,644 | $52,701 | $72,670 | $200,569 | — | — | — | — | — | — |
| Total assets | $6M | $9M | $6M | $6M | $9M | $36M | $30M | $26M | $22M | $16M |
| Total current liabilities | $468,756 | $889,493 | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M |
| Long-term debt | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $5M | $889,493 | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M |
| Shareholders' equity | $987,475 | $8M | $5M | $5M | $9M | $35M | $29M | $24M | $20M | $15M |
| Net debt | -$2M | -$3M | -$3M | -$3M | -$6M | -$29M | -$12M | -$915,000 | -$1M | -$1M |
Anixa Biosciences cash flow, fiscal 2016–2025
| USD | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3M | -$4M | -$4M | -$5M | -$6M | -$5M | -$6M | -$6M | -$7M | -$7M |
| Capital spending | $146,521 | $30,188 | $38,404 | $175,457 | $15,791 | — | — | — | — | — |
| Free cash flow | -$4M | -$4M | -$4M | -$5M | -$6M | — | — | — | — | — |
| Stock-based compensation | — | -$2M | -$9M | -$6M | $4M | $8M | $6M | $4M | $4M | $4M |
| Share buybacks (net) | — | — | — | — | — | — | — | — | -$6,000 | — |
| Free cash flow margin | -1176.1% | -1055.7% | -387.6% | -1966.8% | — | — | — | — | — | — |
How Anixa Biosciences compares
Anixa Biosciences's revenue growth is higher than 26% of Healthcare companies and 21% of the 3,491 companies with a revenue growth figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Revenue growth | 26% | 21% |
| ROE | 17% | 6% |
From Anixa Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.